As of November 6, 2026, Matinas BioPharma Holdings, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 13, 2026, naming 1 departure. The latest filing names Robin L. Smith, leaving (Form 8-K, July 13, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Matinas BioPharma Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Matinas BioPharma Holdings, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-13. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Matinas BioPharma Holdings, Inc. files it.
Also on the record for Matinas BioPharma Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 13, 2026 | Stake report, Schedule 13D/A, by Sanitam Partners LLC | 9.99% of the class | 5%+ stakes | Source |
| July 14, 2026 | Stake report, Schedule 13G, by Hezbay Holdings LLC | 9.54% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by HIGHBRIDGE CAPITAL MANAGEMENT, LLC | — | 5%+ stakes | Source |
| September 25, 2025 | Stake report, Schedule 13D/A, by Hezbay Holdings LLC | 4.99% of the class | 5%+ stakes | Source |
| August 19, 2025 | Stake report, Schedule 13G, by Lazar David E. | 9.81% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Highbridge Capital Management, LLC | 8.4% of the class | 5%+ stakes | Source |
| February 19, 2025 | Form D, private offering | $1.65M sold | Form D page | Source |
Selling to them or working with them? See who runs Matinas BioPharma Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Matinas BioPharma Holdings, Inc. and the records around it.
Matinas BioPharma Holdings, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Lazar David E. also filed stake reports on 8 other companies: HIGHWAY HOLDINGS LTD (Nov 2026), Aterian, Inc. (Sep 2026), MAINZ BIOMED N.V. (Aug 2026)
- Highbridge Capital Management, LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
Watch Matinas BioPharma Holdings, Inc.
Get an email when Matinas BioPharma Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Matinas BioPharma Holdings, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Matinas BioPharma Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Matinas BioPharma Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-13 | Out | 2026-07-12 | 8-K, 2026-07-13 |
New leaders reset buying decisions — get the Full Report on Matinas BioPharma Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Matinas BioPharma Holdings, Inc., with the record behind each one.
Find candidates like senior executive at Matinas BioPharma Holdings, Inc.Every change, in the filing's words
Departing: Robin L. Smith, effective 2026-07-12
Director Resignation On July 11, 2026, Robin L. Smith informed the Board that she resigned from the Board effective July 12, 2026 due to her other professional obligations.
- Jabbour Employment Agreement Amendment On July 10, 2026, the Company and Jerome D. Jabbour, the Company's Chief Executive Officer, entered into the Fourth Amendment (the "Fourth Amendment") to the Employment Agreement between the Company and Mr. Jabbour, dated March 22, 2018 (as previously amended by that certain First Amendment, dated March 3, 2023, that certain Second Amendment, dated April 30, 2025, and that certain Third Amendment, dated December 12, 2025, the "Employment Agreement").
- Prior to the Fourth Amendment, the Employment Agreement provided that if a Change in Control (as defined in the Employment Agreement) occurs on or prior to June 30, 2026 and Mr. Jabbour remains employed by the Company through the date of the Change in Control, he is entitled to payment of a retention bonus in an amount equal to the greater of (i) his target annual bonus for the fiscal year in which such Change in Control occurs, or (ii) $299,000 (the "Retention Bonus").
- Two-thirds of the Retention Bonus will be paid upon the Company's execution of a definitive agreement that, if consummated, would result in a Change in Control, and the remaining one-third would be paid immediately prior to the closing of such Change in Control, so long as, for each payment, Mr. Jabbour has not resigned without Good Reason nor been terminated by the Company for Cause (each as defined in the Employment Agreement).
Tools for this story
Each opens in a new tab, filled in for Matinas BioPharma Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.